Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years old, gender is not limited;

• Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;

• Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.

Locations
Other Locations
China
Nanfang Hospital of Southern Medical University
RECRUITING
Guangzhou
Contact Information
Primary
Zhong Ji, PHD
jizhong22@hotmail.com
020-62787664
Backup
Kaibin Huang
15915751065
Time Frame
Start Date: 2022-05-01
Estimated Completion Date: 2029-05-31
Participants
Target number of participants: 144
Treatments
Experimental: Patients with vertebral atherosclerotic stenosis requiring stent implantation
Referring to the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease, the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus and Subclavian/extracranial vertebral artery stenosis: Chinese expert consensus in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients.
Related Therapeutic Areas
Sponsors
Leads: Nanfang Hospital, Southern Medical University

This content was sourced from clinicaltrials.gov